10-Q: Nascent Biotech Reports Q1 2025 Results, Progresses to Phase 2 Clinical Trials

Nascent Biotech has completed Phase 1 clinical trials for its cancer treatment Pritumumab and is preparing to begin Phase 2 trials, while reporting a net loss of $377,390 for the quarter ending June 30, 2024.

Summary

• Nascent Biotech, a clinical-stage biopharmaceutical company, is developing Pritumumab for brain and pancreatic cancer treatment.
• The company has completed Phase 1 clinical trials and is cleared to begin Phase 2 clinical trials.
• For the quarter ended June 30, 2024, Nascent reported a net loss of $377,390, compared to a net loss of $540,224 for the same period in 2023.
• The company's cash balance decreased from $372,120 to $47,391 during the quarter.
• Total assets were $227,391, and total liabilities were $741,931, resulting in a stockholders' deficit of $514,540.
• The company issued 1,270,000 shares of common stock for the conversion of convertible debt and 338,000 shares to officers and a director for services.
• Nascent is actively researching other cancers that may benefit from Pritumumab and exploring its potential use in treating COVID-19.
• The company estimates it needs to raise $15-20 million to complete Phase 2 clinical studies.

Sentiment

Score: 4

Explanation: The document highlights progress in clinical trials but is overshadowed by significant financial challenges, including a substantial cash decrease, negative working capital, and the need for a large capital raise. The material weaknesses in internal controls also contribute to a negative sentiment.

Positives

• The company has successfully completed Phase 1 clinical trials and is cleared to begin Phase 2 trials.
• The net loss for the quarter decreased compared to the same period last year, from $540,224 to $377,390.
• The company is actively exploring additional applications for Pritumumab, including potential use in COVID-19 treatment and prevention.

Negatives

• The company experienced a significant decrease in cash reserves, from $372,120 to $47,391 during the quarter.
• The company has a negative working capital of $514,540.
• The company has a substantial stockholders' deficit of $514,540.
• The company's disclosure controls and procedures were deemed not effective due to material weaknesses.
• The company has no revenue and is dependent on external funding.

Risks

• The company has a significant working capital deficit and is dependent on raising additional capital to continue operations.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's disclosure controls and procedures are not effective due to material weaknesses.
• The company is reliant on external funding and may need to dilute existing shareholders to raise capital.
• The company has no revenue and is dependent on the success of its clinical trials.

Future Outlook

The company plans to begin Phase 2 clinical trials in late 2024 and estimates it needs to raise $15-20 million to complete these studies. The company will continue to seek outside funding through loans, equity sales, and licensing agreements.

Management Comments

• The company is focused on developing pritumumab for the treatment of patients with brain cancer malignancies such as gliomas and astrocytomas.
• The company has completed phase 1 clinical trials and has submitted to the FDA to begin to begin phase 2 clinical trials.
• The company is investigating the potential utility of pritumumab as both a treatment for COVID-19 and a preventive vaccine for COVID-19.

Industry Context

Nascent Biotech operates in the competitive biopharmaceutical industry, focusing on developing novel cancer treatments. The company's progress to Phase 2 trials is a significant step, but it faces challenges common to early-stage biotech companies, including the need for substantial funding and the risks associated with clinical development. The exploration of Pritumumab for COVID-19 treatment and prevention is a unique approach that could provide a competitive advantage if successful.

Comparison to Industry Standards

• Nascent Biotech's financial position is weaker than many of its peers in the biotech industry, particularly those that have already commercialized products or have secured significant funding.
• Many biotech companies at a similar stage of development have secured larger funding rounds and have more robust cash reserves.
• Companies like Novocure (NVCR) and Inovio Pharmaceuticals (INO), which are also developing novel cancer therapies, have significantly higher market capitalizations and more advanced clinical pipelines.
• Nascent's reliance on external funding and its negative working capital position are significant risks compared to industry standards.
• The company's lack of revenue is typical for a pre-commercial biotech company, but its cash burn rate and need for $15-20 million for Phase 2 trials highlight the financial challenges it faces.

Corporate Governance

Related Party Transactions

• During the three months ended June 30, 2024, two officers and a director were issued 338,000 shares of common stock with a value of $30,920 for service.
• The company has ongoing agreements with officers and directors that entitle them to additional shares to maintain their ownership percentage.

Stakeholder Impact

• Shareholders face potential dilution due to the need for additional capital.
• Employees may be impacted by the company's financial instability and potential restructuring.
• The company's ability to continue clinical trials and develop its product is dependent on securing additional funding.
• The company's financial position may impact its ability to meet its obligations to suppliers and creditors.

Next Steps

• The company plans to begin Phase 2 clinical trials in late 2024.
• The company will seek to raise $15-20 million to fund Phase 2 clinical trials.
• The company will continue to explore the potential of Pritumumab for other cancers and COVID-19.

Key Dates

Keywords

Pritumumab, clinical trials, biotech, cancer treatment, brain cancer, pancreatic cancer, Phase 2, monoclonal antibodies, FDA, COVID-19, financial results, going concern